Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data
Abstract
:1. Introduction
2. Subjects and Methods
2.1. Data Sources and Study Subjects
2.2. Analysis of Domperidone Prescription
2.3. Analysis of Co-Prescribed Medications
2.4. Performance of Electrocardiogram (ECG) Monitoring before or after Domperidone Use
2.5. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Analysing Domperidone Prescription Patterns
3.3. Analysis of Co-Prescribed Medications
3.4. Efforts to Monitor Cardiac Events after Domperidone Use
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Reddymasu, S.C.; Soykan, I.; McCallum, R.W. Domperidone: Review of pharmacology and clinical applications in gastroenterology. Am. J. Gastroenterol. 2007, 102, 2036–2045. [Google Scholar] [CrossRef] [PubMed]
- Lertxundi, U.; Domingo-Echaburu, S.; Soraluce, A.; Garcia, M.; Ruiz-Osante, B.; Aguirre, C. Domperidone in Parkinson’s disease: A perilous arrhythmogenic or the gold standard? Curr. Drug Saf. 2013, 8, 63–68. [Google Scholar] [CrossRef]
- Poovathingal, M.A.; Bhat, R.R. Domperidone induced galactorrhea: An unusual presentation of a common drug. Indian J. Pharmacol. 2013, 45, 307–308. [Google Scholar] [CrossRef]
- Jiménez-Jiménez, F.J.; García-Ruiz, P.J.; Molina, J.A. Drug-induced movement disorders. Drug Saf. 1997, 16, 180–204. [Google Scholar] [CrossRef]
- van Noord, C.; Dieleman, J.P.; van Herpen, G.; Verhamme, K.; Sturkenboom, M.C. Domperidone and ventricular arrhythmia or sudden cardiac death: A population-based case-control study in the Netherlands. Drug Saf. 2010, 33, 1003–1014. [Google Scholar] [CrossRef] [PubMed]
- Osborne, R.J.; Slevin, M.L.; Hunter, R.W.; Hamer, J. Cardiotoxicity of intravenous domperidone. Lancet 1985, 2, 385. [Google Scholar] [CrossRef]
- Johannes, C.B.; Varas-Lorenzo, C.; McQuay, L.J.; Midkiff, K.D.; Fife, D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: A nested case-control study. Pharmacoepidemiol. Drug Saf. 2010, 19, 881–888. [Google Scholar] [CrossRef]
- Claassen, S.; Zünkler, B.J. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 2005, 74, 31–36. [Google Scholar] [CrossRef] [PubMed]
- Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; et al. Heart disease and stroke statistics–2015 update: A report from the American Heart Association. Circulation 2015, 131, e29–e322. [Google Scholar] [CrossRef]
- Aronow, W.S.; Ahn, C.; Mercando, A.D.; Epstein, S.; Kronzon, I. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57, M178–M180. [Google Scholar] [CrossRef] [PubMed]
- Hoffman, C.; Rice, D.; Sung, H.Y. Persons with chronic conditions. Their prevalence and costs. JAMA 1996, 276, 1473–1479. [Google Scholar] [CrossRef] [PubMed]
- Wolff, J.L.; Starfield, B.; Anderson, G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 2002, 162, 2269–2276. [Google Scholar] [CrossRef]
- Field, T.S.; Gurwitz, J.H.; Avorn, J.; McCormick, D.; Jain, S.; Eckler, M.; Benser, M.; Bates, D.W. Risk factors for adverse drug events among nursing home residents. Arch. Intern. Med. 2001, 161, 1629–1634. [Google Scholar] [CrossRef] [PubMed]
- Tinetti, M.E.; Bogardus, S.T.; Agostini, J.V., Jr. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N. Engl. J. Med. 2004, 351, 2870–2874. [Google Scholar] [CrossRef]
- Health Canada, Domperidone Maleate—Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac Arrest)—For Health Professionals. 2015. Available online: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php (accessed on 17 June 2018).
- US Food and Drug Administration. FDA Talk Paper: FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production. 2004. Available online: https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886.htm (accessed on 17 June 2018).
- European Medicines Agency. Review of Domperidone Started. 2013. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/Procedure_started/WC500139769.pdf (accessed on 13 May 2018).
- Ministry of Food and Drug Safety. The Safety Warning Letter. 2014. Available online: http://drug.mfds.go.kr/cdata/r88b78p43s5b33h42h46s62k84d61a10p3f13p61e9j66.pdf (accessed on 13 May 2018).
- National Health Insurance Service. 2018. Available online: http://www.nhis.or.kr/menu/retriveMenuSet.xx?menuId=B2220 (accessed on 7 November 2018).
- Kim, L.; Kim, J.A.; Kim, S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol. Health 2014, 36, e2014008. [Google Scholar] [CrossRef] [PubMed]
- Domperidone IND Packet—FDA. Available online: https://www.fda.gov/media/100064/download (accessed on 2 August 2018).
- Motilium-M® (Original Drug of Domperidone Maleate in South Korea) MFDS Label. Available online: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303107 (accessed on 2 August 2018).
- Ioannou, A.; Jain, A.; Kassianos, G.; Missouris, C. Survey of the use of domperidone and the association with QTc prolongation in general practice. Postgrad. Med. J. 2016, 92, 390–392. [Google Scholar] [CrossRef]
- Lee, J.Y.; Park, K.S. Gender Difference in Functional Gastrointestinal Disorders. Korean J. Gastroenterol. 2018, 72, 163–169. [Google Scholar] [CrossRef] [PubMed]
- Tajiri, K.; Shimizu, Y. Liver physiology and liver diseases in the elderly. World J. Gastroenterol. 2013, 19, 8459–8467. [Google Scholar] [CrossRef]
- Schmucker, D.L. Age-related changes in liver structure and function: Implications for disease? Exp. Gerontol. 2005, 40, 650–659. [Google Scholar] [CrossRef] [PubMed]
- Magueur, E.; Hagege, H.; Attali, P.; Singlas, E.; Etienne, J.P.; Taburet, A.M. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 1991, 31, 185–187. [Google Scholar] [CrossRef] [PubMed]
- Kasten, M.; Chade, A.; Tanner, C.M. Epidemiology of Parkinson’s disease. Handb. Clin. Neurol. 2007, 83, 129–151. [Google Scholar]
- Pringsheim, T.; Jette, N.; Frolkis, A.; Steeves, T.D. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord. 2014, 29, 1583–1590. [Google Scholar] [CrossRef]
- Simeonova, M.; de Vries, F.; Pouwels, S.; Driessen, J.H.M.; Leufkens, H.G.M.; Cadarette, S.M.; Burden, A.M. Increased risk of all-cause mortality associated with domperidone use in Parkinson’s patients: A population-based cohort study in the UK. Br. J. Clin. Pharmacol. 2018, 84, 2551–2561. [Google Scholar] [CrossRef]
- Houghton, L.A.; Heitkemper, M.; Crowell, M.; Emmanuel, A.; Halpert, A.; McRoberts, J.A.; Toner, B. Age, Gender and Women’s Health and the Patient. Gastroenterology 2016. [Google Scholar] [CrossRef]
- Forbes, N.; Cooray, M.; Al-Dabbagh, R.; Yuan, Y.; Tse, F.; Liu, L.W.; Xenodemetropoulos, T. Domperidone Prescribing Practices Exposed Patients to Cardiac Risk despite a “Black Box” Warning: A Canadian Tertiary Care Center Study. Can. J. Gastroenterol. Hepatol. 2016, 2016, 2937678. [Google Scholar] [CrossRef]
- Anderson, M.E.; Al-Khatib, S.M.; Roden, D.M.; Califf, R.M. Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. Am. Heart J. 2002, 144, 769–781. [Google Scholar] [CrossRef]
- Berger, F.; Saâïd, S.; van Gelder, T.; Stricker, B.; Becker, M.; van den Bemt, P. Media attention regarding sudden cardiac death associated with domperidone use does not affect in hospital ECG recording. Pharmacoepidemiol. Drug Saf. 2017, 26, 1418–1424. [Google Scholar] [CrossRef]
- Frommeyer, G.; Fischer, C.; Ellermann, C.; Dechering, D.G.; Kochhäuser, S.; Lange, P.S.; Wasmer, K.; Fehr, M.; Eckardt, L. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovasc. Toxicol. 2018, 18, 84–90. [Google Scholar] [CrossRef]
- Boyce, M.J.; Baisley, K.J.; Warrington, S.J. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: A randomized, placebo-controlled, double-blind, crossover study. Br. J. Clin. Pharmacol. 2012, 73, 411–421. [Google Scholar] [CrossRef]
- Teeling, M.; MacAvin, M.J.; Bennett, K. Impact of safety warnings on domperidone prescribing in Ireland. Ir. J. Med. Sci. 2018, 187, 281–285. [Google Scholar] [CrossRef]
Characteristics of Patients | No. of Patients (%) | OR (95% CI) | ||
---|---|---|---|---|
2011 | 2016 | |||
Domperidone use | Non-user | 903,934 (84.2) | 1,315,362 (99.1) | Reference |
User | 169,249 (15.8) | 12,093 (0.9) | 0.049 (0.048, 0.050) | |
Sex | Male | 57,402 (33.9) | 4417 (36.5) | Reference |
Female | 111,847 (66.1) | 7676 (63.5) | 0.89 (0.86, 0.93) | |
Age group | ≤65 and <70 | 57,299 (33.9) | 2865 (23.7) | Reference |
≤70 and <75 | 51,959 (30.7) | 2985 (24.7) | 1.15 (1.09, 1.21) | |
≤75 | 59,991 (35.4) | 6243 (51.6) | 2.08 (1.99, 2.18) | |
Insurance type | Health insurance | 154,471 (91.3) | 10,592 (87.6) | Reference |
Medical aid | 14,536 (8.6) | 1468 (12.1) | 1.47 (1.39, 1.56) | |
Veterans | 242 (0.1) | 33 (0.3) | 1.99 (1.38, 2.86) |
Characteristics of Patients | No. of Patients/Prescription (%) | OR (95% CI) | ||
---|---|---|---|---|
2011 | 2016 | |||
Number of comorbid diseases a | 0 | 108,368 (64.0) | 8363 (69.2) | Reference |
1 | 47,614 (28.1) | 3268 (27.0) | 0.89 (0.85, 0.93) | |
2 | 12,013 (7.1) | 429 (3.5) | 0.46 (0.42, 0.51) | |
3 | 1203 (0.7) | 33 (0.3) | 0.36 (0.25, 0.50) | |
4 | 51 (<0.1) | 0 (0.0) | 0.00 (0.00, 0.00) | |
Type of comorbid disease | Hepatic disease | 47,900 (28.3) | 1683 (13.9) | 0.41 (0.39, 0.43) |
Renal disease | 15,181 (9.0) | 871 (7.2) | 0.79 (0.73, 0.85) | |
Cardiac arrhythmia | 6489 (3.8) | 195 (1.6) | 0.41 (0.36, 0.48) | |
Parkinson’s disease | 5883 (3.5) | 1476 (12.2) | 3.86 (3.63, 4.10) | |
Maximum dose of domperidone in each prescriptions b | ≤30 mg/day | 550,690 (91.2) | 24,423 (99.2) | Reference |
>30 and ≤40 mg/day | 11,556 (1.9) | 98 (0.4) | 0.19 (0.16, 0.23) | |
>40 mg/day | 41,716 (6.9) | 102 (0.4) | 0.06 (0.05, 0.07) | |
Maximum continuous duration of prescribed domperidone a | ≤7 days | 104,824 (61.9) | 6872 (56.8) | Reference |
>7 days | 64,425 (38.1) | 5221 (43.2) | 1.24 (1.19, 1.28) |
Characteristics of Patients | No. of Prescriptions | ||
---|---|---|---|
2011 (N = 603,962) | 2016 (N = 24,623) | ||
Number of co-prescribing medications | 0 | 450,217 | 13,959 |
1 | 141,383 | 7631 | |
2 | 11,791 | 2179 | |
≥3 | 571 | 854 |
Drug Category (ATC a Code) | No. of Prescriptions | |
---|---|---|
2011 (N = 603,962) | 2016 (N = 24,623) | |
Drugs for acid related disorders (A02) | 96,031 | 2811 |
Diuretics (C03) | 28,225 | 4085 |
Antibacterials for systemic use (J01) | 17,080 | 1112 |
Psychoanaleptics (N06) | 16,143 | 2470 |
Antihistamines for systemic use (R06) | 8765 | 143 |
Antimycotics for systemic use (J02) | 4214 | 156 |
Calcium channel blockers (C08) | 3669 | 963 |
Antithrombotic agents (B01) | 3478 | 594 |
Psycholeptics (N05) | 2853 | 2145 |
Drugs for obstructive airway disease (R03) | 2478 | 150 |
Miscellaneous | 341 | 67 |
Drugs for cardiac disease (C01) | 292 | 160 |
Analgesics (N02) | 92 | 6 |
Antivirals for systemic use (J05) | 0 | 0 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rhew, K.; Han, N.; Oh, J.M. Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data. Int. J. Environ. Res. Public Health 2019, 16, 2985. https://doi.org/10.3390/ijerph16162985
Rhew K, Han N, Oh JM. Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data. International Journal of Environmental Research and Public Health. 2019; 16(16):2985. https://doi.org/10.3390/ijerph16162985
Chicago/Turabian StyleRhew, Kiyon, Nayoung Han, and Jung Mi Oh. 2019. "Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data" International Journal of Environmental Research and Public Health 16, no. 16: 2985. https://doi.org/10.3390/ijerph16162985